Bottom line
IYH vs FTXH: the short answer
IYH (iShares U.S. Healthcare ETF) and FTXH (First Trust Nasdaq Pharmaceuticals ETF) share a meaningful slice of their top holdings — about 50% by weight.
But IYH is far broader, holding 103 positions to 51 for FTXH, so beyond the top names it adds exposure FTXH doesn't have.
IYH is cheaper at 0.37% vs 0.6% — a difference of $23 a year per $10,000 invested.
Over five years, IYH returned +7.0% a year vs +6.5% for FTXH.
Updated Nov 19, 2026
IYH vs FTXH side by side
| IYH | FTXH | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | iShares | First Trust |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.37% | 0.6% |
| Annual cost per $10k | $37 | $60 |
| 10-yr cost on $10k (prospectus) | $468 | — |
| Max front load | None | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +13.1% | +24.0% |
| 5-yr return (annualized) | +7.0% | +6.5% |
| 10-yr return (annualized) | +9.4% | — |
| Best quarter | +15.3% | +18.3% |
| Worst quarter | −12.7% | −17.4% |
| Net assets (fund) | $3.6B | $36.2M |
| Number of holdings | 103 | 51 |
| Portfolio turnover | 3% | 35% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | IYH | FTXH | Difference |
|---|---|---|---|
| 2025 | +13.1% | +24.0% | −10.9% |
| 2024 | +3.1% | +3.0% | +0.1% |
| 2023 | +2.1% | −1.4% | +3.5% |
| 2022 | −4.4% | +2.5% | −6.9% |
| 2021 | +23.4% | +6.1% | +17.3% |
| 2020 | +15.5% | +10.9% | +4.6% |
| 2019 | +20.8% | +22.4% | −1.5% |
| 2018 | +5.9% | −8.4% | +14.2% |
| 2017 | +22.3% | +18.8% | +3.5% |
Source: Fund prospectus bar charts
Holdings overlap
10 of IYH's top 25 holdings also appear in FTXH's top 25.
| Holding | IYH | FTXH |
|---|---|---|
| Eli Lilly And Company | 15.11% | 7.77% |
| Johnson & Johnson | 10.17% | 6.96% |
| Abbvie Inc. | 7.32% | 7.39% |
| Merck & Co., Inc. | 5.31% | 7.07% |
| Amgen Inc. | 3.42% | 3.18% |
| Gilead Sciences, Inc. | 2.66% | 2.89% |
| Pfizer Inc. | 2.35% | 2.97% |
| Bristol-myers Squibb Company | 2.20% | 6.29% |
| Vertex Pharmaceuticals Incorporated | 2.00% | 3.41% |
| Regeneron Pharmaceuticals, Inc. | 1.27% | 2.72% |
Source: SEC Form N-PORT
IYH top 10
- Eli Lilly And Company — 15.11%
- Johnson & Johnson — 10.17%
- Abbvie Inc. — 7.32%
- Unitedhealth Group Incorporated — 6.16%
- Merck & Co., Inc. — 5.31%
- Thermo Fisher Scientific Incorporated — 3.52%
- Amgen Inc. — 3.42%
- Abbott Laboratories — 3.02%
- Gilead Sciences, Inc. — 2.66%
- Pfizer Inc. — 2.35%
FTXH top 10
- Eli Lilly & Company — 7.77%
- Abbvie Inc — 7.39%
- Merck & Company Inc — 7.07%
- Johnson & Johnson — 6.96%
- Bristol-myers Squibb Company — 6.29%
- Biogen Inc — 3.84%
- Viatris Inc — 3.62%
- Cardinal Health Inc — 3.53%
- Vertex Pharmaceuticals Inc — 3.41%
- Amgen Inc — 3.18%
FAQ
What is the difference between IYH and FTXH?
Which is cheaper, IYH or FTXH?
Should I own both IYH and FTXH?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.